JeffreyMStatlandMD
Neurology • Kansas City, KSNeuromuscular Medicine
Assistant Professor, Neurology, University of Kansas Medical Center
Dr. Statland is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3901 Rainbow Blvd
Stop 2012
Kansas City, KS 66160Phone+1 913-588-6970Fax+1 913-588-0609
Education & Training
University of Kansas School of MedicineResidency, Neurology, 2007 - 2010- University of Kansas School of MedicineResidency, Internal Medicine, 2006 - 2007
- University of Kansas School of MedicineClass of 2005
Certifications & Licensure
KS State Medical License 2014 - 2025
MO State Medical License 2022 - 2025
CO State Medical License 2022 - 2023
WA State Medical License 2019 - 2023
NY State Medical License 2010 - 2014- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Rasch-analysis of Clinical Severity in FSHD Start of enrollment: 2016 Mar 01
- Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD Start of enrollment: 2018 Mar 05
- Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis Start of enrollment: 2018 Jun 11
- Join now to see all
Publications & Presentations
PubMed
- 45 citationsMuscle pathology grade for facioscapulohumeral muscular dystrophy biopsies.Jeffrey Statland, Bharati Shah, Don Henderson, Silvère M. van der Maarel, Stephen J. Tapscott
Muscle & Nerve. 2015-10-01 - 8 citationsElevated plasma complement components in facioscapulohumeral dystrophy.Chao-Jen Wong, Leo Wang, V Michael Holers, Ashley Frazer-Abel, Silvère M van der Maarel
Human Molecular Genetics. 2022-06-04 - 12 citationsAntisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial.Charles A Thornton, Richard Thomas Moxley 3rd, Katy Eichinger, Chad Heatwole, Laurence Mignon
The Lancet. Neurology. 2023-03-01
Press Mentions
Avidity Biosciences Enters into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers for Future Clinical Trial UseAugust 16th, 2021- Muscular Dystrophy Association Virtual Conference to Feature Latest Advances in Neuromuscular Therapy and Clinical CareMarch 8th, 2021
- FSHD Society Is Funding the Expansion of the FSHD Clinical Trial Research NetworkAugust 11th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
